Cymabay Therapeutics (CBAY) 10-K2023 FY Annual report

Filed: 28 Feb 24, 4:31pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abatement, advisor, Alfasigma, alleviate, amassed, Amgen, anda, Anderson, Antitrust, arbitration, architecture, Arlington, asa, ASC, attack, attendant, authoritative, automated, awardswere, binding, body, book, bundled, burden, catego, CCPA, cent, CFA, Child, Circle, CMC, CMMI, Colorado, combat, combinationof, comment, confirmatory, conjunction, Connecticut, constraint, consummated, consummating, consummation, contemplated, context, contractor, counterparty, coveragewithout, cybersecurity, dark, decree, delete, denominated, deploying, deter, DGCL, disaster, discourage, dispose, Dissenting, distinct, doesnot, doubt, Dumbarton, duty, Eastern, Eikon, enclosed, encryption, escalate, excise, experimental, Extortion, fiduciary, fifteen, forecasting, Fremont, furniture, generallythree, Gilead, graph, hardware, Harish, Harmonisation, honor, hospitalization, HSR, IDEAL, identification, implanted, incidental, infused, inhaled, injected, instilled, intelligence, Interagency, IXIC, judgement, land, learning, MAA, machine, macroeconomic, manual, margin, MBA, merger, MHRA, Mine, minute, misleading, modification, monumental, mutual, NBI, nearest, negation, newly, NOL, nonstatutory, obstruction, ofan, ofASC, outset, Pacific, par, Parcel, Parking, pendency, penetration, pharmacology, plaintiff, platform, predominant, prespecified, Pugh, purported, Qualitative, Quantitative, randomly, ransomware, redemption, reinforced, reinvestment, relatedto, resale, rescissory, retaliatory, retroactive, rounded, satisfieseach, SeeNote, seller, sellsome, Shantharam, sought, SSP, standalone, sterling, stricter, sublease, subleased, successor, Supplementary, taxation, TB, tender, tendered, thereon, threat, timeframe, UCLA, UK, unaccompanied, unavailable, unconditional, unqualified, unreasonably, Unresolved, unused, validly, viable, waiting, web, whichever, wholly, wider, withheld, Worst, writing, wrongdoing, yearfrom

Removed: adapted, adult, Affymetrix, agree, answer, apportioned, beta, blood, Blvd, Brexit, cancelable, card, career, cell, chemical, closure, collective, Commerce, compare, confidence, Daniel, degradation, derived, diary, discovered, dispensed, District, efficiently, enact, establishment, evolve, exploring, expressing, filer, Florida, foresee, franchise, gap, Gateway, geographic, globe, gut, Harmonization, home, hormone, implicit, ingredient, initiate, internationally, manager, mandatory, McIntire, mechanism, medicine, Menold, morbidity, negotiated, nondeductible, Northern, Orlando, outbreak, outpatient, pandemic, partner, payer, Poverty, precautionary, predictive, preventive, quarantine, regulator, remote, remotely, rental, San, spread, square, stringent, sublicense, sugar, Suite, synthetic, UCDA, undisclosed, unique, unspecified, utility, view, warranted, Zoosk

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CBAY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Sujal Shah., President and Chief Executive Officer and Harish Shantharam, Chief Financial Officer of CymaBay Therapeutics, Inc. (the “Company”), each hereby certifies that, to the best of his knowledge:

The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned have set their hands hereto as of the 28^th day of February, 2024.

/s/ Sujal Shah

Sujal Shah

President and Chief Executive Officer

(Principal Executive Officer)

/s/ Harish Shantharam

Harish Shantharam

Chief Financial Officer

(Principal Financial and Accounting Officer)

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of CymaBay Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.